Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
33,560
archived clinical trials in
Neurology

Community Participation Transition After Stroke
Feasibility of a Novel Intervention to Improve Participation After Stroke
Status: Enrolling
Updated:  4/23/2018
Washington University School of Medicine
mi
from
Saint Louis, MO
Community Participation Transition After Stroke
Feasibility of a Novel Intervention to Improve Participation After Stroke
Status: Enrolling
Updated: 4/23/2018
Washington University School of Medicine
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Repeat of: A Study to Evaluate Efficacy and Safety of Sublingual TNX-102 SL Tablet Taken at Bedtime in Patients With Fibromyalgia
A Phase 3, Double-Blind, Randomized, Multicenter, Placebo-Controlled Study To Evaluate The EFFIcacy and Safety of TNX-102 SL Tablets Taken Daily At Bedtime In Patients With FibRoMyalgia
Status: Enrolling
Updated:  4/23/2018
Clinical Research Facility
mi
from
Birmingham, AL
Repeat of: A Study to Evaluate Efficacy and Safety of Sublingual TNX-102 SL Tablet Taken at Bedtime in Patients With Fibromyalgia
A Phase 3, Double-Blind, Randomized, Multicenter, Placebo-Controlled Study To Evaluate The EFFIcacy and Safety of TNX-102 SL Tablets Taken Daily At Bedtime In Patients With FibRoMyalgia
Status: Enrolling
Updated: 4/23/2018
Clinical Research Facility
mi
from
Birmingham, AL
Click here to add this to my saved trials
Repeat of: A Study to Evaluate Efficacy and Safety of Sublingual TNX-102 SL Tablet Taken at Bedtime in Patients With Fibromyalgia
A Phase 3, Double-Blind, Randomized, Multicenter, Placebo-Controlled Study To Evaluate The EFFIcacy and Safety of TNX-102 SL Tablets Taken Daily At Bedtime In Patients With FibRoMyalgia
Status: Enrolling
Updated:  4/23/2018
Clinical Research Facility
mi
from
Phoenix, AZ
Repeat of: A Study to Evaluate Efficacy and Safety of Sublingual TNX-102 SL Tablet Taken at Bedtime in Patients With Fibromyalgia
A Phase 3, Double-Blind, Randomized, Multicenter, Placebo-Controlled Study To Evaluate The EFFIcacy and Safety of TNX-102 SL Tablets Taken Daily At Bedtime In Patients With FibRoMyalgia
Status: Enrolling
Updated: 4/23/2018
Clinical Research Facility
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Repeat of: A Study to Evaluate Efficacy and Safety of Sublingual TNX-102 SL Tablet Taken at Bedtime in Patients With Fibromyalgia
A Phase 3, Double-Blind, Randomized, Multicenter, Placebo-Controlled Study To Evaluate The EFFIcacy and Safety of TNX-102 SL Tablets Taken Daily At Bedtime In Patients With FibRoMyalgia
Status: Enrolling
Updated:  4/23/2018
Clinical Research Facility
mi
from
Oceanside, CA
Repeat of: A Study to Evaluate Efficacy and Safety of Sublingual TNX-102 SL Tablet Taken at Bedtime in Patients With Fibromyalgia
A Phase 3, Double-Blind, Randomized, Multicenter, Placebo-Controlled Study To Evaluate The EFFIcacy and Safety of TNX-102 SL Tablets Taken Daily At Bedtime In Patients With FibRoMyalgia
Status: Enrolling
Updated: 4/23/2018
Clinical Research Facility
mi
from
Oceanside, CA
Click here to add this to my saved trials
Repeat of: A Study to Evaluate Efficacy and Safety of Sublingual TNX-102 SL Tablet Taken at Bedtime in Patients With Fibromyalgia
A Phase 3, Double-Blind, Randomized, Multicenter, Placebo-Controlled Study To Evaluate The EFFIcacy and Safety of TNX-102 SL Tablets Taken Daily At Bedtime In Patients With FibRoMyalgia
Status: Enrolling
Updated:  4/23/2018
Clinical Research Facility
mi
from
San Diego, CA
Repeat of: A Study to Evaluate Efficacy and Safety of Sublingual TNX-102 SL Tablet Taken at Bedtime in Patients With Fibromyalgia
A Phase 3, Double-Blind, Randomized, Multicenter, Placebo-Controlled Study To Evaluate The EFFIcacy and Safety of TNX-102 SL Tablets Taken Daily At Bedtime In Patients With FibRoMyalgia
Status: Enrolling
Updated: 4/23/2018
Clinical Research Facility
mi
from
San Diego, CA
Click here to add this to my saved trials
Repeat of: A Study to Evaluate Efficacy and Safety of Sublingual TNX-102 SL Tablet Taken at Bedtime in Patients With Fibromyalgia
A Phase 3, Double-Blind, Randomized, Multicenter, Placebo-Controlled Study To Evaluate The EFFIcacy and Safety of TNX-102 SL Tablets Taken Daily At Bedtime In Patients With FibRoMyalgia
Status: Enrolling
Updated:  4/23/2018
Clinical Research Facility
mi
from
Brandon, FL
Repeat of: A Study to Evaluate Efficacy and Safety of Sublingual TNX-102 SL Tablet Taken at Bedtime in Patients With Fibromyalgia
A Phase 3, Double-Blind, Randomized, Multicenter, Placebo-Controlled Study To Evaluate The EFFIcacy and Safety of TNX-102 SL Tablets Taken Daily At Bedtime In Patients With FibRoMyalgia
Status: Enrolling
Updated: 4/23/2018
Clinical Research Facility
mi
from
Brandon, FL
Click here to add this to my saved trials
Repeat of: A Study to Evaluate Efficacy and Safety of Sublingual TNX-102 SL Tablet Taken at Bedtime in Patients With Fibromyalgia
A Phase 3, Double-Blind, Randomized, Multicenter, Placebo-Controlled Study To Evaluate The EFFIcacy and Safety of TNX-102 SL Tablets Taken Daily At Bedtime In Patients With FibRoMyalgia
Status: Enrolling
Updated:  4/23/2018
Clinical Research Facility
mi
from
DeLand, FL
Repeat of: A Study to Evaluate Efficacy and Safety of Sublingual TNX-102 SL Tablet Taken at Bedtime in Patients With Fibromyalgia
A Phase 3, Double-Blind, Randomized, Multicenter, Placebo-Controlled Study To Evaluate The EFFIcacy and Safety of TNX-102 SL Tablets Taken Daily At Bedtime In Patients With FibRoMyalgia
Status: Enrolling
Updated: 4/23/2018
Clinical Research Facility
mi
from
DeLand, FL
Click here to add this to my saved trials
Repeat of: A Study to Evaluate Efficacy and Safety of Sublingual TNX-102 SL Tablet Taken at Bedtime in Patients With Fibromyalgia
A Phase 3, Double-Blind, Randomized, Multicenter, Placebo-Controlled Study To Evaluate The EFFIcacy and Safety of TNX-102 SL Tablets Taken Daily At Bedtime In Patients With FibRoMyalgia
Status: Enrolling
Updated:  4/23/2018
Clinical Research Facility
mi
from
Ocala, FL
Repeat of: A Study to Evaluate Efficacy and Safety of Sublingual TNX-102 SL Tablet Taken at Bedtime in Patients With Fibromyalgia
A Phase 3, Double-Blind, Randomized, Multicenter, Placebo-Controlled Study To Evaluate The EFFIcacy and Safety of TNX-102 SL Tablets Taken Daily At Bedtime In Patients With FibRoMyalgia
Status: Enrolling
Updated: 4/23/2018
Clinical Research Facility
mi
from
Ocala, FL
Click here to add this to my saved trials
Repeat of: A Study to Evaluate Efficacy and Safety of Sublingual TNX-102 SL Tablet Taken at Bedtime in Patients With Fibromyalgia
A Phase 3, Double-Blind, Randomized, Multicenter, Placebo-Controlled Study To Evaluate The EFFIcacy and Safety of TNX-102 SL Tablets Taken Daily At Bedtime In Patients With FibRoMyalgia
Status: Enrolling
Updated:  4/23/2018
Clinical Research Facility
mi
from
Orlando, FL
Repeat of: A Study to Evaluate Efficacy and Safety of Sublingual TNX-102 SL Tablet Taken at Bedtime in Patients With Fibromyalgia
A Phase 3, Double-Blind, Randomized, Multicenter, Placebo-Controlled Study To Evaluate The EFFIcacy and Safety of TNX-102 SL Tablets Taken Daily At Bedtime In Patients With FibRoMyalgia
Status: Enrolling
Updated: 4/23/2018
Clinical Research Facility
mi
from
Orlando, FL
Click here to add this to my saved trials
Repeat of: A Study to Evaluate Efficacy and Safety of Sublingual TNX-102 SL Tablet Taken at Bedtime in Patients With Fibromyalgia
A Phase 3, Double-Blind, Randomized, Multicenter, Placebo-Controlled Study To Evaluate The EFFIcacy and Safety of TNX-102 SL Tablets Taken Daily At Bedtime In Patients With FibRoMyalgia
Status: Enrolling
Updated:  4/23/2018
Clinical Research Facility
mi
from
Tampa, FL
Repeat of: A Study to Evaluate Efficacy and Safety of Sublingual TNX-102 SL Tablet Taken at Bedtime in Patients With Fibromyalgia
A Phase 3, Double-Blind, Randomized, Multicenter, Placebo-Controlled Study To Evaluate The EFFIcacy and Safety of TNX-102 SL Tablets Taken Daily At Bedtime In Patients With FibRoMyalgia
Status: Enrolling
Updated: 4/23/2018
Clinical Research Facility
mi
from
Tampa, FL
Click here to add this to my saved trials
Repeat of: A Study to Evaluate Efficacy and Safety of Sublingual TNX-102 SL Tablet Taken at Bedtime in Patients With Fibromyalgia
A Phase 3, Double-Blind, Randomized, Multicenter, Placebo-Controlled Study To Evaluate The EFFIcacy and Safety of TNX-102 SL Tablets Taken Daily At Bedtime In Patients With FibRoMyalgia
Status: Enrolling
Updated:  4/23/2018
Clinical Research Facility
mi
from
West Palm Beach, FL
Repeat of: A Study to Evaluate Efficacy and Safety of Sublingual TNX-102 SL Tablet Taken at Bedtime in Patients With Fibromyalgia
A Phase 3, Double-Blind, Randomized, Multicenter, Placebo-Controlled Study To Evaluate The EFFIcacy and Safety of TNX-102 SL Tablets Taken Daily At Bedtime In Patients With FibRoMyalgia
Status: Enrolling
Updated: 4/23/2018
Clinical Research Facility
mi
from
West Palm Beach, FL
Click here to add this to my saved trials
Repeat of: A Study to Evaluate Efficacy and Safety of Sublingual TNX-102 SL Tablet Taken at Bedtime in Patients With Fibromyalgia
A Phase 3, Double-Blind, Randomized, Multicenter, Placebo-Controlled Study To Evaluate The EFFIcacy and Safety of TNX-102 SL Tablets Taken Daily At Bedtime In Patients With FibRoMyalgia
Status: Enrolling
Updated:  4/23/2018
Clinical Research Facility
mi
from
Indianapolis, IN
Repeat of: A Study to Evaluate Efficacy and Safety of Sublingual TNX-102 SL Tablet Taken at Bedtime in Patients With Fibromyalgia
A Phase 3, Double-Blind, Randomized, Multicenter, Placebo-Controlled Study To Evaluate The EFFIcacy and Safety of TNX-102 SL Tablets Taken Daily At Bedtime In Patients With FibRoMyalgia
Status: Enrolling
Updated: 4/23/2018
Clinical Research Facility
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Repeat of: A Study to Evaluate Efficacy and Safety of Sublingual TNX-102 SL Tablet Taken at Bedtime in Patients With Fibromyalgia
A Phase 3, Double-Blind, Randomized, Multicenter, Placebo-Controlled Study To Evaluate The EFFIcacy and Safety of TNX-102 SL Tablets Taken Daily At Bedtime In Patients With FibRoMyalgia
Status: Enrolling
Updated:  4/23/2018
Clinical Research Facility
mi
from
Jackson, MS
Repeat of: A Study to Evaluate Efficacy and Safety of Sublingual TNX-102 SL Tablet Taken at Bedtime in Patients With Fibromyalgia
A Phase 3, Double-Blind, Randomized, Multicenter, Placebo-Controlled Study To Evaluate The EFFIcacy and Safety of TNX-102 SL Tablets Taken Daily At Bedtime In Patients With FibRoMyalgia
Status: Enrolling
Updated: 4/23/2018
Clinical Research Facility
mi
from
Jackson, MS
Click here to add this to my saved trials
Repeat of: A Study to Evaluate Efficacy and Safety of Sublingual TNX-102 SL Tablet Taken at Bedtime in Patients With Fibromyalgia
A Phase 3, Double-Blind, Randomized, Multicenter, Placebo-Controlled Study To Evaluate The EFFIcacy and Safety of TNX-102 SL Tablets Taken Daily At Bedtime In Patients With FibRoMyalgia
Status: Enrolling
Updated:  4/23/2018
Clinical Research Facility
mi
from
Las Vegas, NV
Repeat of: A Study to Evaluate Efficacy and Safety of Sublingual TNX-102 SL Tablet Taken at Bedtime in Patients With Fibromyalgia
A Phase 3, Double-Blind, Randomized, Multicenter, Placebo-Controlled Study To Evaluate The EFFIcacy and Safety of TNX-102 SL Tablets Taken Daily At Bedtime In Patients With FibRoMyalgia
Status: Enrolling
Updated: 4/23/2018
Clinical Research Facility
mi
from
Las Vegas, NV
Click here to add this to my saved trials
Repeat of: A Study to Evaluate Efficacy and Safety of Sublingual TNX-102 SL Tablet Taken at Bedtime in Patients With Fibromyalgia
A Phase 3, Double-Blind, Randomized, Multicenter, Placebo-Controlled Study To Evaluate The EFFIcacy and Safety of TNX-102 SL Tablets Taken Daily At Bedtime In Patients With FibRoMyalgia
Status: Enrolling
Updated:  4/23/2018
Clinical Research Facility
mi
from
Cedarhurst, NY
Repeat of: A Study to Evaluate Efficacy and Safety of Sublingual TNX-102 SL Tablet Taken at Bedtime in Patients With Fibromyalgia
A Phase 3, Double-Blind, Randomized, Multicenter, Placebo-Controlled Study To Evaluate The EFFIcacy and Safety of TNX-102 SL Tablets Taken Daily At Bedtime In Patients With FibRoMyalgia
Status: Enrolling
Updated: 4/23/2018
Clinical Research Facility
mi
from
Cedarhurst, NY
Click here to add this to my saved trials
Repeat of: A Study to Evaluate Efficacy and Safety of Sublingual TNX-102 SL Tablet Taken at Bedtime in Patients With Fibromyalgia
A Phase 3, Double-Blind, Randomized, Multicenter, Placebo-Controlled Study To Evaluate The EFFIcacy and Safety of TNX-102 SL Tablets Taken Daily At Bedtime In Patients With FibRoMyalgia
Status: Enrolling
Updated:  4/23/2018
Clinical Research Facility
mi
from
Williamsville, NY
Repeat of: A Study to Evaluate Efficacy and Safety of Sublingual TNX-102 SL Tablet Taken at Bedtime in Patients With Fibromyalgia
A Phase 3, Double-Blind, Randomized, Multicenter, Placebo-Controlled Study To Evaluate The EFFIcacy and Safety of TNX-102 SL Tablets Taken Daily At Bedtime In Patients With FibRoMyalgia
Status: Enrolling
Updated: 4/23/2018
Clinical Research Facility
mi
from
Williamsville, NY
Click here to add this to my saved trials
Repeat of: A Study to Evaluate Efficacy and Safety of Sublingual TNX-102 SL Tablet Taken at Bedtime in Patients With Fibromyalgia
A Phase 3, Double-Blind, Randomized, Multicenter, Placebo-Controlled Study To Evaluate The EFFIcacy and Safety of TNX-102 SL Tablets Taken Daily At Bedtime In Patients With FibRoMyalgia
Status: Enrolling
Updated:  4/23/2018
Clinical Research Facility
mi
from
Raleigh, NC
Repeat of: A Study to Evaluate Efficacy and Safety of Sublingual TNX-102 SL Tablet Taken at Bedtime in Patients With Fibromyalgia
A Phase 3, Double-Blind, Randomized, Multicenter, Placebo-Controlled Study To Evaluate The EFFIcacy and Safety of TNX-102 SL Tablets Taken Daily At Bedtime In Patients With FibRoMyalgia
Status: Enrolling
Updated: 4/23/2018
Clinical Research Facility
mi
from
Raleigh, NC
Click here to add this to my saved trials
Repeat of: A Study to Evaluate Efficacy and Safety of Sublingual TNX-102 SL Tablet Taken at Bedtime in Patients With Fibromyalgia
A Phase 3, Double-Blind, Randomized, Multicenter, Placebo-Controlled Study To Evaluate The EFFIcacy and Safety of TNX-102 SL Tablets Taken Daily At Bedtime In Patients With FibRoMyalgia
Status: Enrolling
Updated:  4/23/2018
Clinical Research Facility
mi
from
Fargo, ND
Repeat of: A Study to Evaluate Efficacy and Safety of Sublingual TNX-102 SL Tablet Taken at Bedtime in Patients With Fibromyalgia
A Phase 3, Double-Blind, Randomized, Multicenter, Placebo-Controlled Study To Evaluate The EFFIcacy and Safety of TNX-102 SL Tablets Taken Daily At Bedtime In Patients With FibRoMyalgia
Status: Enrolling
Updated: 4/23/2018
Clinical Research Facility
mi
from
Fargo, ND
Click here to add this to my saved trials
Repeat of: A Study to Evaluate Efficacy and Safety of Sublingual TNX-102 SL Tablet Taken at Bedtime in Patients With Fibromyalgia
A Phase 3, Double-Blind, Randomized, Multicenter, Placebo-Controlled Study To Evaluate The EFFIcacy and Safety of TNX-102 SL Tablets Taken Daily At Bedtime In Patients With FibRoMyalgia
Status: Enrolling
Updated:  4/23/2018
Clinical Research Facility
mi
from
Canton, OH
Repeat of: A Study to Evaluate Efficacy and Safety of Sublingual TNX-102 SL Tablet Taken at Bedtime in Patients With Fibromyalgia
A Phase 3, Double-Blind, Randomized, Multicenter, Placebo-Controlled Study To Evaluate The EFFIcacy and Safety of TNX-102 SL Tablets Taken Daily At Bedtime In Patients With FibRoMyalgia
Status: Enrolling
Updated: 4/23/2018
Clinical Research Facility
mi
from
Canton, OH
Click here to add this to my saved trials
Repeat of: A Study to Evaluate Efficacy and Safety of Sublingual TNX-102 SL Tablet Taken at Bedtime in Patients With Fibromyalgia
A Phase 3, Double-Blind, Randomized, Multicenter, Placebo-Controlled Study To Evaluate The EFFIcacy and Safety of TNX-102 SL Tablets Taken Daily At Bedtime In Patients With FibRoMyalgia
Status: Enrolling
Updated:  4/23/2018
Clinical Research Facility
mi
from
Cincinnati, OH
Repeat of: A Study to Evaluate Efficacy and Safety of Sublingual TNX-102 SL Tablet Taken at Bedtime in Patients With Fibromyalgia
A Phase 3, Double-Blind, Randomized, Multicenter, Placebo-Controlled Study To Evaluate The EFFIcacy and Safety of TNX-102 SL Tablets Taken Daily At Bedtime In Patients With FibRoMyalgia
Status: Enrolling
Updated: 4/23/2018
Clinical Research Facility
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Repeat of: A Study to Evaluate Efficacy and Safety of Sublingual TNX-102 SL Tablet Taken at Bedtime in Patients With Fibromyalgia
A Phase 3, Double-Blind, Randomized, Multicenter, Placebo-Controlled Study To Evaluate The EFFIcacy and Safety of TNX-102 SL Tablets Taken Daily At Bedtime In Patients With FibRoMyalgia
Status: Enrolling
Updated:  4/23/2018
Clinical Research Facility
mi
from
Medford, OR
Repeat of: A Study to Evaluate Efficacy and Safety of Sublingual TNX-102 SL Tablet Taken at Bedtime in Patients With Fibromyalgia
A Phase 3, Double-Blind, Randomized, Multicenter, Placebo-Controlled Study To Evaluate The EFFIcacy and Safety of TNX-102 SL Tablets Taken Daily At Bedtime In Patients With FibRoMyalgia
Status: Enrolling
Updated: 4/23/2018
Clinical Research Facility
mi
from
Medford, OR
Click here to add this to my saved trials
Repeat of: A Study to Evaluate Efficacy and Safety of Sublingual TNX-102 SL Tablet Taken at Bedtime in Patients With Fibromyalgia
A Phase 3, Double-Blind, Randomized, Multicenter, Placebo-Controlled Study To Evaluate The EFFIcacy and Safety of TNX-102 SL Tablets Taken Daily At Bedtime In Patients With FibRoMyalgia
Status: Enrolling
Updated:  4/23/2018
Clinical Research Facility
mi
from
Portland, OR
Repeat of: A Study to Evaluate Efficacy and Safety of Sublingual TNX-102 SL Tablet Taken at Bedtime in Patients With Fibromyalgia
A Phase 3, Double-Blind, Randomized, Multicenter, Placebo-Controlled Study To Evaluate The EFFIcacy and Safety of TNX-102 SL Tablets Taken Daily At Bedtime In Patients With FibRoMyalgia
Status: Enrolling
Updated: 4/23/2018
Clinical Research Facility
mi
from
Portland, OR
Click here to add this to my saved trials
Repeat of: A Study to Evaluate Efficacy and Safety of Sublingual TNX-102 SL Tablet Taken at Bedtime in Patients With Fibromyalgia
A Phase 3, Double-Blind, Randomized, Multicenter, Placebo-Controlled Study To Evaluate The EFFIcacy and Safety of TNX-102 SL Tablets Taken Daily At Bedtime In Patients With FibRoMyalgia
Status: Enrolling
Updated:  4/23/2018
Clinical Research Facility
mi
from
Salem, OR
Repeat of: A Study to Evaluate Efficacy and Safety of Sublingual TNX-102 SL Tablet Taken at Bedtime in Patients With Fibromyalgia
A Phase 3, Double-Blind, Randomized, Multicenter, Placebo-Controlled Study To Evaluate The EFFIcacy and Safety of TNX-102 SL Tablets Taken Daily At Bedtime In Patients With FibRoMyalgia
Status: Enrolling
Updated: 4/23/2018
Clinical Research Facility
mi
from
Salem, OR
Click here to add this to my saved trials
Repeat of: A Study to Evaluate Efficacy and Safety of Sublingual TNX-102 SL Tablet Taken at Bedtime in Patients With Fibromyalgia
A Phase 3, Double-Blind, Randomized, Multicenter, Placebo-Controlled Study To Evaluate The EFFIcacy and Safety of TNX-102 SL Tablets Taken Daily At Bedtime In Patients With FibRoMyalgia
Status: Enrolling
Updated:  4/23/2018
Clinical Research Facility
mi
from
Allentown, PA
Repeat of: A Study to Evaluate Efficacy and Safety of Sublingual TNX-102 SL Tablet Taken at Bedtime in Patients With Fibromyalgia
A Phase 3, Double-Blind, Randomized, Multicenter, Placebo-Controlled Study To Evaluate The EFFIcacy and Safety of TNX-102 SL Tablets Taken Daily At Bedtime In Patients With FibRoMyalgia
Status: Enrolling
Updated: 4/23/2018
Clinical Research Facility
mi
from
Allentown, PA
Click here to add this to my saved trials
Repeat of: A Study to Evaluate Efficacy and Safety of Sublingual TNX-102 SL Tablet Taken at Bedtime in Patients With Fibromyalgia
A Phase 3, Double-Blind, Randomized, Multicenter, Placebo-Controlled Study To Evaluate The EFFIcacy and Safety of TNX-102 SL Tablets Taken Daily At Bedtime In Patients With FibRoMyalgia
Status: Enrolling
Updated:  4/23/2018
Clinical Research Facility
mi
from
Warwick, RI
Repeat of: A Study to Evaluate Efficacy and Safety of Sublingual TNX-102 SL Tablet Taken at Bedtime in Patients With Fibromyalgia
A Phase 3, Double-Blind, Randomized, Multicenter, Placebo-Controlled Study To Evaluate The EFFIcacy and Safety of TNX-102 SL Tablets Taken Daily At Bedtime In Patients With FibRoMyalgia
Status: Enrolling
Updated: 4/23/2018
Clinical Research Facility
mi
from
Warwick, RI
Click here to add this to my saved trials
Repeat of: A Study to Evaluate Efficacy and Safety of Sublingual TNX-102 SL Tablet Taken at Bedtime in Patients With Fibromyalgia
A Phase 3, Double-Blind, Randomized, Multicenter, Placebo-Controlled Study To Evaluate The EFFIcacy and Safety of TNX-102 SL Tablets Taken Daily At Bedtime In Patients With FibRoMyalgia
Status: Enrolling
Updated:  4/23/2018
Clinical Research Facility
mi
from
Chattanooga, TN
Repeat of: A Study to Evaluate Efficacy and Safety of Sublingual TNX-102 SL Tablet Taken at Bedtime in Patients With Fibromyalgia
A Phase 3, Double-Blind, Randomized, Multicenter, Placebo-Controlled Study To Evaluate The EFFIcacy and Safety of TNX-102 SL Tablets Taken Daily At Bedtime In Patients With FibRoMyalgia
Status: Enrolling
Updated: 4/23/2018
Clinical Research Facility
mi
from
Chattanooga, TN
Click here to add this to my saved trials
Repeat of: A Study to Evaluate Efficacy and Safety of Sublingual TNX-102 SL Tablet Taken at Bedtime in Patients With Fibromyalgia
A Phase 3, Double-Blind, Randomized, Multicenter, Placebo-Controlled Study To Evaluate The EFFIcacy and Safety of TNX-102 SL Tablets Taken Daily At Bedtime In Patients With FibRoMyalgia
Status: Enrolling
Updated:  4/23/2018
Clinical Research Facility
mi
from
Dallas, TX
Repeat of: A Study to Evaluate Efficacy and Safety of Sublingual TNX-102 SL Tablet Taken at Bedtime in Patients With Fibromyalgia
A Phase 3, Double-Blind, Randomized, Multicenter, Placebo-Controlled Study To Evaluate The EFFIcacy and Safety of TNX-102 SL Tablets Taken Daily At Bedtime In Patients With FibRoMyalgia
Status: Enrolling
Updated: 4/23/2018
Clinical Research Facility
mi
from
Dallas, TX
Click here to add this to my saved trials
Repeat of: A Study to Evaluate Efficacy and Safety of Sublingual TNX-102 SL Tablet Taken at Bedtime in Patients With Fibromyalgia
A Phase 3, Double-Blind, Randomized, Multicenter, Placebo-Controlled Study To Evaluate The EFFIcacy and Safety of TNX-102 SL Tablets Taken Daily At Bedtime In Patients With FibRoMyalgia
Status: Enrolling
Updated:  4/23/2018
Clinical Research Facility
mi
from
Salt Lake City, UT
Repeat of: A Study to Evaluate Efficacy and Safety of Sublingual TNX-102 SL Tablet Taken at Bedtime in Patients With Fibromyalgia
A Phase 3, Double-Blind, Randomized, Multicenter, Placebo-Controlled Study To Evaluate The EFFIcacy and Safety of TNX-102 SL Tablets Taken Daily At Bedtime In Patients With FibRoMyalgia
Status: Enrolling
Updated: 4/23/2018
Clinical Research Facility
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Repeat of: A Study to Evaluate Efficacy and Safety of Sublingual TNX-102 SL Tablet Taken at Bedtime in Patients With Fibromyalgia
A Phase 3, Double-Blind, Randomized, Multicenter, Placebo-Controlled Study To Evaluate The EFFIcacy and Safety of TNX-102 SL Tablets Taken Daily At Bedtime In Patients With FibRoMyalgia
Status: Enrolling
Updated:  4/23/2018
Clinical Research Facility
mi
from
Seattle, WA
Repeat of: A Study to Evaluate Efficacy and Safety of Sublingual TNX-102 SL Tablet Taken at Bedtime in Patients With Fibromyalgia
A Phase 3, Double-Blind, Randomized, Multicenter, Placebo-Controlled Study To Evaluate The EFFIcacy and Safety of TNX-102 SL Tablets Taken Daily At Bedtime In Patients With FibRoMyalgia
Status: Enrolling
Updated: 4/23/2018
Clinical Research Facility
mi
from
Seattle, WA
Click here to add this to my saved trials
Repeat of: A Study to Evaluate Efficacy and Safety of Sublingual TNX-102 SL Tablet Taken at Bedtime in Patients With Fibromyalgia
A Phase 3, Double-Blind, Randomized, Multicenter, Placebo-Controlled Study To Evaluate The EFFIcacy and Safety of TNX-102 SL Tablets Taken Daily At Bedtime In Patients With FibRoMyalgia
Status: Enrolling
Updated:  4/23/2018
Clinical Research Facility
mi
from
Kenosha, WI
Repeat of: A Study to Evaluate Efficacy and Safety of Sublingual TNX-102 SL Tablet Taken at Bedtime in Patients With Fibromyalgia
A Phase 3, Double-Blind, Randomized, Multicenter, Placebo-Controlled Study To Evaluate The EFFIcacy and Safety of TNX-102 SL Tablets Taken Daily At Bedtime In Patients With FibRoMyalgia
Status: Enrolling
Updated: 4/23/2018
Clinical Research Facility
mi
from
Kenosha, WI
Click here to add this to my saved trials
Repeat of: A Study to Evaluate Efficacy and Safety of Sublingual TNX-102 SL Tablet Taken at Bedtime in Patients With Fibromyalgia
A Phase 3, Double-Blind, Randomized, Multicenter, Placebo-Controlled Study To Evaluate The EFFIcacy and Safety of TNX-102 SL Tablets Taken Daily At Bedtime In Patients With FibRoMyalgia
Status: Enrolling
Updated:  4/23/2018
Clinical Research Facility
mi
from
Evansville, IN
Repeat of: A Study to Evaluate Efficacy and Safety of Sublingual TNX-102 SL Tablet Taken at Bedtime in Patients With Fibromyalgia
A Phase 3, Double-Blind, Randomized, Multicenter, Placebo-Controlled Study To Evaluate The EFFIcacy and Safety of TNX-102 SL Tablets Taken Daily At Bedtime In Patients With FibRoMyalgia
Status: Enrolling
Updated: 4/23/2018
Clinical Research Facility
mi
from
Evansville, IN
Click here to add this to my saved trials
Repeat of: A Study to Evaluate Efficacy and Safety of Sublingual TNX-102 SL Tablet Taken at Bedtime in Patients With Fibromyalgia
A Phase 3, Double-Blind, Randomized, Multicenter, Placebo-Controlled Study To Evaluate The EFFIcacy and Safety of TNX-102 SL Tablets Taken Daily At Bedtime In Patients With FibRoMyalgia
Status: Enrolling
Updated:  4/23/2018
Clinical Research Facility
mi
from
Mount Pleasant, SC
Repeat of: A Study to Evaluate Efficacy and Safety of Sublingual TNX-102 SL Tablet Taken at Bedtime in Patients With Fibromyalgia
A Phase 3, Double-Blind, Randomized, Multicenter, Placebo-Controlled Study To Evaluate The EFFIcacy and Safety of TNX-102 SL Tablets Taken Daily At Bedtime In Patients With FibRoMyalgia
Status: Enrolling
Updated: 4/23/2018
Clinical Research Facility
mi
from
Mount Pleasant, SC
Click here to add this to my saved trials
rTMS in Spasmodic Dysphonia
Repetitive Transcranial Magnetic Stimulation in Spasmodic Dysphonia
Status: Enrolling
Updated:  4/24/2018
Noninvasive Neuromodulation Laboratory
mi
from
Minneapolis, MN
rTMS in Spasmodic Dysphonia
Repetitive Transcranial Magnetic Stimulation in Spasmodic Dysphonia
Status: Enrolling
Updated: 4/24/2018
Noninvasive Neuromodulation Laboratory
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Phenotypic and Genetic Factors in Autism Spectrum Disorders
Phenotypic and Genetic Factors in Autism Spectrum Disorders
Status: Enrolling
Updated:  4/25/2018
Children's Hospital Boston
mi
from
Boston, MA
Phenotypic and Genetic Factors in Autism Spectrum Disorders
Phenotypic and Genetic Factors in Autism Spectrum Disorders
Status: Enrolling
Updated: 4/25/2018
Children's Hospital Boston
mi
from
Boston, MA
Click here to add this to my saved trials
GNE-Myopathy Disease Monitoring Program (GNEM-DMP): A Registry and Prospective Observational Natural History Study to Assess GNE Myopathy or Hereditary Inclusion Body Myopathy (HIBM)
GNE-Myopathy Disease Monitoring Program (GNEM-DMP): A Registry and Prospective Observational Natural History Study to Assess GNE Myopathy or Hereditary Inclusion Body Myopathy (HIBM)
Status: Enrolling
Updated:  4/25/2018
University of California, Irvine
mi
from
Irvine, CA
GNE-Myopathy Disease Monitoring Program (GNEM-DMP): A Registry and Prospective Observational Natural History Study to Assess GNE Myopathy or Hereditary Inclusion Body Myopathy (HIBM)
GNE-Myopathy Disease Monitoring Program (GNEM-DMP): A Registry and Prospective Observational Natural History Study to Assess GNE Myopathy or Hereditary Inclusion Body Myopathy (HIBM)
Status: Enrolling
Updated: 4/25/2018
University of California, Irvine
mi
from
Irvine, CA
Click here to add this to my saved trials
GNE-Myopathy Disease Monitoring Program (GNEM-DMP): A Registry and Prospective Observational Natural History Study to Assess GNE Myopathy or Hereditary Inclusion Body Myopathy (HIBM)
GNE-Myopathy Disease Monitoring Program (GNEM-DMP): A Registry and Prospective Observational Natural History Study to Assess GNE Myopathy or Hereditary Inclusion Body Myopathy (HIBM)
Status: Enrolling
Updated:  4/25/2018
Bulgarian Neuromuscular Disease Association
mi
from
Sofia,
GNE-Myopathy Disease Monitoring Program (GNEM-DMP): A Registry and Prospective Observational Natural History Study to Assess GNE Myopathy or Hereditary Inclusion Body Myopathy (HIBM)
GNE-Myopathy Disease Monitoring Program (GNEM-DMP): A Registry and Prospective Observational Natural History Study to Assess GNE Myopathy or Hereditary Inclusion Body Myopathy (HIBM)
Status: Enrolling
Updated: 4/25/2018
Bulgarian Neuromuscular Disease Association
mi
from
Sofia,
Click here to add this to my saved trials
Neurotoxin and Physical Therapy
Synergistic Effects of Neurotoxin and Physical Therapy
Status: Enrolling
Updated:  4/25/2018
University of Florida
mi
from
Gainesville, FL
Neurotoxin and Physical Therapy
Synergistic Effects of Neurotoxin and Physical Therapy
Status: Enrolling
Updated: 4/25/2018
University of Florida
mi
from
Gainesville, FL
Click here to add this to my saved trials
Noradrenergic and Stress-Related Etiologies of Chronic Fatigue Syndrome
Noradrenergic and Stress-Related Etiologies of Chronic Fatigue Syndrome
Status: Enrolling
Updated:  4/25/2018
Vanderbilt University Medical Center
mi
from
Nashville, TN
Noradrenergic and Stress-Related Etiologies of Chronic Fatigue Syndrome
Noradrenergic and Stress-Related Etiologies of Chronic Fatigue Syndrome
Status: Enrolling
Updated: 4/25/2018
Vanderbilt University Medical Center
mi
from
Nashville, TN
Click here to add this to my saved trials
A Pilot Study of Dexmedetomidine-Propofol in Children Undergoing Magnetic Resonance Imaging
A Pilot Study of Dexmedetomidine-Propofol in Children Undergoing Magnetic Resonance Imaging
Status: Enrolling
Updated:  4/25/2018
Boston Children's Hospital
mi
from
Boston, MA
A Pilot Study of Dexmedetomidine-Propofol in Children Undergoing Magnetic Resonance Imaging
A Pilot Study of Dexmedetomidine-Propofol in Children Undergoing Magnetic Resonance Imaging
Status: Enrolling
Updated: 4/25/2018
Boston Children's Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Evaluation of a Novel Integrative and Intensive Virtual Rehabilitation Program for Service Members Post TBI
Evaluation of a Novel Integrative and Intensive Virtual Rehabilitation Program for Service Members Post TBI
Status: Enrolling
Updated:  4/25/2018
Walter Reed National Military Medical Center
mi
from
Bethesda, MD
Evaluation of a Novel Integrative and Intensive Virtual Rehabilitation Program for Service Members Post TBI
Evaluation of a Novel Integrative and Intensive Virtual Rehabilitation Program for Service Members Post TBI
Status: Enrolling
Updated: 4/25/2018
Walter Reed National Military Medical Center
mi
from
Bethesda, MD
Click here to add this to my saved trials
MRI to Assess the Effects of Dysautonomia and Chronic Nausea on Brain Transmitters
Study Title: Brain Transmitters/Metabolites, Magnetic Resonance Spectroscopy, and Brain Connectivity: Diagnostic Strategies to Study the Effects of Non-Pharmacologic Therapies for Dysautonomia and Chronic Nausea
Status: Enrolling
Updated:  4/26/2018
Wake Forest University Baptist Medical Center
mi
from
Winston-Salem, NC
MRI to Assess the Effects of Dysautonomia and Chronic Nausea on Brain Transmitters
Study Title: Brain Transmitters/Metabolites, Magnetic Resonance Spectroscopy, and Brain Connectivity: Diagnostic Strategies to Study the Effects of Non-Pharmacologic Therapies for Dysautonomia and Chronic Nausea
Status: Enrolling
Updated: 4/26/2018
Wake Forest University Baptist Medical Center
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
Effect of Yoga on Mood and Quality of Life in Patients With Refractory Epilepsy
Effect of Yoga on Mood and Quality of Life in Patients With Refractory Epilepsy
Status: Enrolling
Updated:  4/26/2018
University of Kansas Medical Center
mi
from
Kansas City, KA
Effect of Yoga on Mood and Quality of Life in Patients With Refractory Epilepsy
Effect of Yoga on Mood and Quality of Life in Patients With Refractory Epilepsy
Status: Enrolling
Updated: 4/26/2018
University of Kansas Medical Center
mi
from
Kansas City, KA
Click here to add this to my saved trials
Turmeric as Treatment in Epilepsy
Turmeric as Treatment in Epilepsy
Status: Enrolling
Updated:  4/26/2018
New York University School of Medicine
mi
from
New York, NY
Turmeric as Treatment in Epilepsy
Turmeric as Treatment in Epilepsy
Status: Enrolling
Updated: 4/26/2018
New York University School of Medicine
mi
from
New York, NY
Click here to add this to my saved trials
Optical Stimulation in Peripheral Nerves for Select Rhizotomy Procedures
Optical Stimulation in Peripheral Nerves in Selective Rhizotomy Cases
Status: Enrolling
Updated:  4/27/2018
Vanderbilt University
mi
from
Nashville, TN
Optical Stimulation in Peripheral Nerves for Select Rhizotomy Procedures
Optical Stimulation in Peripheral Nerves in Selective Rhizotomy Cases
Status: Enrolling
Updated: 4/27/2018
Vanderbilt University
mi
from
Nashville, TN
Click here to add this to my saved trials
Sapropterin as a Treatment for Autistic Disorder
Sapropterin as a Treatment for Autistic Disorder: A Phase II Randomized, Double-Blind, Placebo-Controlled Trial
Status: Enrolling
Updated:  4/27/2018
The Children's Health Council
mi
from
Palo Alto, CA
Sapropterin as a Treatment for Autistic Disorder
Sapropterin as a Treatment for Autistic Disorder: A Phase II Randomized, Double-Blind, Placebo-Controlled Trial
Status: Enrolling
Updated: 4/27/2018
The Children's Health Council
mi
from
Palo Alto, CA
Click here to add this to my saved trials
Safety Follow-up Study for Subjects With Agitation Associated With Dementia of the Alzheimer's Type Who Previously Participated in a Double-blind Trial of Brexpiprazole or Placebo
A 2-Month, Observational, Rollover Trial to Evaluate the Safety of Subjects With Agitation Associated With Dementia of the Alzheimer's Type Who Were Previously Treated With Brexpiprazole (OPC 34712) or Placebo in a Phase 3, Double-blind Trial
Status: Enrolling
Updated:  4/27/2018
Clinical Research Facility
mi
from
Tuscaloosa, AL
Safety Follow-up Study for Subjects With Agitation Associated With Dementia of the Alzheimer's Type Who Previously Participated in a Double-blind Trial of Brexpiprazole or Placebo
A 2-Month, Observational, Rollover Trial to Evaluate the Safety of Subjects With Agitation Associated With Dementia of the Alzheimer's Type Who Were Previously Treated With Brexpiprazole (OPC 34712) or Placebo in a Phase 3, Double-blind Trial
Status: Enrolling
Updated: 4/27/2018
Clinical Research Facility
mi
from
Tuscaloosa, AL
Click here to add this to my saved trials
Safety Follow-up Study for Subjects With Agitation Associated With Dementia of the Alzheimer's Type Who Previously Participated in a Double-blind Trial of Brexpiprazole or Placebo
A 2-Month, Observational, Rollover Trial to Evaluate the Safety of Subjects With Agitation Associated With Dementia of the Alzheimer's Type Who Were Previously Treated With Brexpiprazole (OPC 34712) or Placebo in a Phase 3, Double-blind Trial
Status: Enrolling
Updated:  4/27/2018
Clinical Research Facility
mi
from
Costa Mesa, CA
Safety Follow-up Study for Subjects With Agitation Associated With Dementia of the Alzheimer's Type Who Previously Participated in a Double-blind Trial of Brexpiprazole or Placebo
A 2-Month, Observational, Rollover Trial to Evaluate the Safety of Subjects With Agitation Associated With Dementia of the Alzheimer's Type Who Were Previously Treated With Brexpiprazole (OPC 34712) or Placebo in a Phase 3, Double-blind Trial
Status: Enrolling
Updated: 4/27/2018
Clinical Research Facility
mi
from
Costa Mesa, CA
Click here to add this to my saved trials
Safety Follow-up Study for Subjects With Agitation Associated With Dementia of the Alzheimer's Type Who Previously Participated in a Double-blind Trial of Brexpiprazole or Placebo
A 2-Month, Observational, Rollover Trial to Evaluate the Safety of Subjects With Agitation Associated With Dementia of the Alzheimer's Type Who Were Previously Treated With Brexpiprazole (OPC 34712) or Placebo in a Phase 3, Double-blind Trial
Status: Enrolling
Updated:  4/27/2018
Clinical Research Facility
mi
from
Orange, CA
Safety Follow-up Study for Subjects With Agitation Associated With Dementia of the Alzheimer's Type Who Previously Participated in a Double-blind Trial of Brexpiprazole or Placebo
A 2-Month, Observational, Rollover Trial to Evaluate the Safety of Subjects With Agitation Associated With Dementia of the Alzheimer's Type Who Were Previously Treated With Brexpiprazole (OPC 34712) or Placebo in a Phase 3, Double-blind Trial
Status: Enrolling
Updated: 4/27/2018
Clinical Research Facility
mi
from
Orange, CA
Click here to add this to my saved trials
Safety Follow-up Study for Subjects With Agitation Associated With Dementia of the Alzheimer's Type Who Previously Participated in a Double-blind Trial of Brexpiprazole or Placebo
A 2-Month, Observational, Rollover Trial to Evaluate the Safety of Subjects With Agitation Associated With Dementia of the Alzheimer's Type Who Were Previously Treated With Brexpiprazole (OPC 34712) or Placebo in a Phase 3, Double-blind Trial
Status: Enrolling
Updated:  4/27/2018
Clinical Research Facility
mi
from
Redlands, CA
Safety Follow-up Study for Subjects With Agitation Associated With Dementia of the Alzheimer's Type Who Previously Participated in a Double-blind Trial of Brexpiprazole or Placebo
A 2-Month, Observational, Rollover Trial to Evaluate the Safety of Subjects With Agitation Associated With Dementia of the Alzheimer's Type Who Were Previously Treated With Brexpiprazole (OPC 34712) or Placebo in a Phase 3, Double-blind Trial
Status: Enrolling
Updated: 4/27/2018
Clinical Research Facility
mi
from
Redlands, CA
Click here to add this to my saved trials
Safety Follow-up Study for Subjects With Agitation Associated With Dementia of the Alzheimer's Type Who Previously Participated in a Double-blind Trial of Brexpiprazole or Placebo
A 2-Month, Observational, Rollover Trial to Evaluate the Safety of Subjects With Agitation Associated With Dementia of the Alzheimer's Type Who Were Previously Treated With Brexpiprazole (OPC 34712) or Placebo in a Phase 3, Double-blind Trial
Status: Enrolling
Updated:  4/27/2018
Clinical Research Facility
mi
from
Bradenton, FL
Safety Follow-up Study for Subjects With Agitation Associated With Dementia of the Alzheimer's Type Who Previously Participated in a Double-blind Trial of Brexpiprazole or Placebo
A 2-Month, Observational, Rollover Trial to Evaluate the Safety of Subjects With Agitation Associated With Dementia of the Alzheimer's Type Who Were Previously Treated With Brexpiprazole (OPC 34712) or Placebo in a Phase 3, Double-blind Trial
Status: Enrolling
Updated: 4/27/2018
Clinical Research Facility
mi
from
Bradenton, FL
Click here to add this to my saved trials